Safety profile of upadacitinib in rheumatoid arthritis: integrated analysis from the SELECT phase III clinical programme

Objectives This integrated analysis presents the safety profile of upadacitinib, a Janus kinase inhibitor, at 15 mg and 30 mg once daily in patients with moderately to severely active rheumatoid arthritis (RA). Methods Treatment-emergent adverse events (TEAEs) and laboratory data from five randomised, placebo- or active-controlled phase III trials of upadacitinib for patients with RA were analysed and summarised. Exposure-adjusted event rates are shown for placebo (three trials; 12/14 weeks), methotrexate (two trials; mean exposure: 36 weeks), adalimumab (one trial; mean exposure: 42 weeks), upadacitinib 15 mg (five trials; mean exposure: 53 weeks) and upadacitinib 30 mg (four trials; mean exposure: 59 weeks). Results 3834 patients received one or more doses of upadacitinib 15 mg (n=2630) or 30 mg (n=1204), for a total of 4020.1 patient-years of exposure. Upper respiratory tract infection, nasopharyngitis and urinary tract infection were the most commonly reported TEAEs with upadacitinib. Rates of serious infection were similar between upadacitinib 15 mg and adalimumab but higher compared with methotrexate. Rates of herpes zoster and creatine phosphokinase (CPK) elevations were higher in both upadacitinib groups versus methotrexate and adalimumab, and rates of gastrointestinal perforations were higher with upadacitinib 30 mg. Rates of deaths, malignancies, adjudicated major adverse cardiovascular events (MACEs) and venous thromboembolic events (VTEs) were similar across treatment groups. Conclusion In the phase III clinical programme for RA, patients receiving upadacitinib had an increased risk of herpes zoster and CPK elevation versus adalimumab. Rates of malignancies, MACEs and VTEs were similar among patients receiving upadacitinib, methotrexate or adalimumab. Trial registration numbers SELECT-EARLY: NCT02706873; SELECT-NEXT: NCT02675426; SELECT-COMPARE: NCT02629159; SELECT-MONOTHERAPY: NCT02706951; SELECT-BEYOND: NCT02706847.

[1]  V. Strand,et al.  Efficacy and Safety of Upadacitinib Monotherapy in Methotrexate‐Naive Patients With Moderately‐to‐Severely Active Rheumatoid Arthritis (SELECT‐EARLY): A Multicenter, Multi‐Country, Randomized, Double‐Blind, Active Comparator–Controlled Trial , 2020, Arthritis & rheumatology.

[2]  Yoshiya Tanaka.  A review of upadacitinib in rheumatoid arthritis , 2020, Modern rheumatology.

[3]  Yoshiya Tanaka,et al.  Safety profile of baricitinib in Japanese patients with active rheumatoid arthritis with over 1.6 years median time in treatment: An integrated analysis of Phases 2 and 3 trials , 2020, Modern rheumatology.

[4]  C. Peterfy,et al.  Upadacitinib Versus Placebo or Adalimumab in Patients With Rheumatoid Arthritis and an Inadequate Response to Methotrexate: Results of a Phase III, Double‐Blind, Randomized Controlled Trial , 2019, Arthritis & rheumatology.

[5]  P. Emery,et al.  Upadacitinib as monotherapy in patients with active rheumatoid arthritis and inadequate response to methotrexate (SELECT-MONOTHERAPY): a randomised, placebo-controlled, double-blind phase 3 study , 2019, The Lancet.

[6]  M. Genovese,et al.  THU0078 SAFETY PROFILE OF BARICITINIB FOR THE TREATMENT OF RHEUMATOID ARTHRITIS UP TO 7 YEARS: AN UPDATED INTEGRATED SAFETY ANALYSIS , 2019, Poster Presentations.

[7]  William J. Housley,et al.  FRI0131 ELUCIDATING THE MECHANISM UNDERLYING CREATINE PHOSPHOKINASE UPREGULATION WITH UPADACITINIB , 2019, Poster Presentations.

[8]  Stanley B. Cohen,et al.  Safety and efficacy of tofacitinib for up to 9.5 years in the treatment of rheumatoid arthritis: final results of a global, open-label, long-term extension study , 2019, Arthritis Research & Therapy.

[9]  V. Strand,et al.  059 A phase 3, randomised controlled trial comparing upadacitinib monotherapy to MTX monotherapy in MTX-naïve patients with active rheumatoid arthritis , 2019, Rheumatology.

[10]  H. Yamanaka,et al.  Efficacy and safety of tofacitinib for the treatment of rheumatoid arthritis in patients from the Asia‐Pacific region: Post‐hoc analyses of pooled clinical study data , 2019, International journal of rheumatic diseases.

[11]  M. Genovese,et al.  Safety Profile of Baricitinib in Patients with Active Rheumatoid Arthritis with over 2 Years Median Time in Treatment , 2018, The Journal of Rheumatology.

[12]  L. Olson,et al.  In vitro and in vivo characterization of the JAK1 selectivity of upadacitinib (ABT-494) , 2018, BMC Rheumatology.

[13]  Yoshiya Tanaka,et al.  Efficacy and safety of baricitinib in Japanese patients with rheumatoid arthritis: Subgroup analyses of four multinational phase 3 randomized trials , 2018, Modern rheumatology.

[14]  S. Hider,et al.  Thromboembolism with Janus Kinase (JAK) Inhibitors for Rheumatoid Arthritis: How Real is the Risk? , 2018, Drug Safety.

[15]  J. Kremer,et al.  Safety and efficacy of upadacitinib in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying anti-rheumatic drugs (SELECT-NEXT): a randomised, double-blind, placebo-controlled phase 3 trial , 2018, The Lancet.

[16]  M. Genovese,et al.  Safety and efficacy of upadacitinib in patients with active rheumatoid arthritis refractory to biologic disease-modifying anti-rheumatic drugs (SELECT-BEYOND): a double-blind, randomised controlled phase 3 trial , 2018, The Lancet.

[17]  J. O’Shea,et al.  JAK inhibition as a therapeutic strategy for immune and inflammatory diseases , 2017, Nature Reviews Drug Discovery.

[18]  Yoshiya Tanaka,et al.  Herpes Zoster and Tofacitinib: Clinical Outcomes and the Risk of Concomitant Therapy , 2017, Arthritis & rheumatology.

[19]  K. Winthrop.  The emerging safety profile of JAK inhibitors in rheumatic disease , 2017, Nature Reviews Rheumatology.

[20]  Stanley B. Cohen,et al.  Long-term safety of tofacitinib for the treatment of rheumatoid arthritis up to 8.5 years: integrated analysis of data from the global clinical trials , 2017, Annals of the rheumatic diseases.

[21]  M. Aringer,et al.  Risk for lower intestinal perforations in patients with rheumatoid arthritis treated with tocilizumab in comparison to treatment with other biologic or conventional synthetic DMARDs , 2016, Annals of the rheumatic diseases.

[22]  S. Bernatsky,et al.  Brief Report: Risk of Gastrointestinal Perforation Among Rheumatoid Arthritis Patients Receiving Tofacitinib, Tocilizumab, or Other Biologic Treatments , 2016, Arthritis & rheumatology.

[23]  Acr Announcements.  ACR Announcements , 2015, Arthritis & Rheumatology.

[24]  H. Yamanaka,et al.  Herpes Zoster and Tofacitinib Therapy in Patients With Rheumatoid Arthritis , 2014, Arthritis & rheumatology.

[25]  S. Schneeweiss,et al.  Risk of Venous Thromboembolism in Patients With Rheumatoid Arthritis , 2013, Arthritis care & research.

[26]  M. Neovius,et al.  Risk of venous thromboembolism in patients with rheumatoid arthritis and association with disease duration and hospitalization. , 2012, JAMA.

[27]  A. Silman,et al.  Rheumatoid arthritis classifi cation criteria : an American College of Rheumatology / European League Against Rheumatism collaborative initiative , 2010 .